e-Drug3D

2083

SORAVTANSINE

INN
SORAVTANSINE
MIRVETUXIMAB SORAVTANSINE-GYNX

cas 796073-69-3

CLASS

ANTINEOPLASTIC
FOLATE RECEPTOR ALPHA (FRALPHA)-DIRECTED ANTIBODY
MICROTUBULE INHIBITOR CONJUGATE
ANTIBODY-DRUG CONJUGATE (ADC)
DM4 IS A MAYTANSINE DERIVATIVE
DM4 DISRUPTS THE MICROTUBULE NETWORK WITHIN THE CELL, RESULTING IN CELL CYCLE ARREST AND APOPTOTIC CELL DEATH
TREATMENT OF ADULT PATIENTS WITH FR ALPHA POSITIVE, PLATINUM-RESISTANT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER

ROUTE (list)

INJECTION

NATURAL MOLECULE (link)

ATC code

L01FX26

PK parameters

Cl 13.8 LITER / HOUR
PPB 99 PERCENT
t1/2 67.2 HOUR

Target

TARGET TUBULIN

DrugCentral

TUBULIN TBB1_HUMAN INHIBITOR UNIPROT P04350

Download SDF file

Maytansine, N2-deacetyl-N2-(4-mercapto-4-methyl-1-oxopentyl)- (9CI, ACI)

Formula:
C38H54ClN3O10S

Calculated chemical properties:

MW 780.36
NB_atoms 53
XLogP 5.00
PSA 146.757
NB_HD 2
NB_HA 13
fsp3 0.63
Lipinski(0=no;1=yes) 0

FDA
NDA 761310 (label) INN (MIRVETUXIMAB SORAVTANSINE-GYNX) ELAHERE (IMMUNOGEN INC) APPROVAL= AP YEAR= 2022 NEWMOLECULARENTITY